(Q46645573)

23 December 2017

title

The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma (English)

1 reference

23 December 2017

1 reference

fluticasone propionate

1 reference

Randolph Malone

1

1 reference

23 December 2017

Craig LaForce

2

1 reference

23 December 2017

Sai Nimmagadda

3

1 reference

23 December 2017

Lynne Schoaf

4

1 reference

23 December 2017

Karen House

5

1 reference

23 December 2017

Anna Ellsworth

6

1 reference

23 December 2017

Paul Dorinsky

7

1 reference

23 December 2017

publication date

1 July 2005

1 reference

23 December 2017

Annals of Allergy, Asthma & Immunology

published in

1 reference

23 December 2017

volume

95

1 reference

23 December 2017

issue

1

1 reference

23 December 2017

page(s)

66-71

1 reference

23 December 2017

Balancing safety and efficacy in the treatment of pediatric asthma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961190-8

7 January 2021

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961190-8

7 January 2021

Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961190-8

7 January 2021

Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961190-8

7 January 2021

Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961190-8

7 January 2021

Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961190-8

7 January 2021

Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961190-8

7 January 2021

Salmeterol inhibition of mediator release from human lung mast cells by beta-adrenoceptor-dependent and independent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961190-8

7 January 2021

Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961190-8

7 January 2021

10.1016/S1081-1206(10)61190-8

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017